Göker, Erdem
Ege University
2 papers on CoChatORCID 0000-0001-6180-713X
Most cited papers
- Verified
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 433
- Verified
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Goss, G. D., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Guclu, S., et al. (2018) · JAMA Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 55
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free